SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD

Welcome to OncLive On Air®!

In today’s episode, supported by Immatics, we spoke with Jason Luke, MD, about the development of the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in the ongoing phase 3 SUPRAME trial (NCT06743126) in patients with previously treated, unresectable or metastatic cutaneous melanoma.

In our conversation, Dr Luke discussed the rationale for evaluating IMA203 in patients with cutaneous melanoma, the mechanism of action of this novel drug, the design of this study, earlier data that support the continued investigation of this agent in this population, and what these findings may mean for the future of TCR therapy in melanoma.

____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by Immatics. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

Editor’s note: Dr Luke is currently the chief medical officer of Strand Therapeutics. At the time of filming this interview, he was the associate director of clinical research and the director of the Immunotherapy and Drug Development Center at the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.